CAS: 940908-79-2; (2R,3R,4R,5R)-5-(4-Amino-2-Oxopyrimidin-1(2H)-yl)-4-Fluoro-2-((Isobutyryloxy)Methyl)-4-Methyltetrahydrofuran-3-Yl Isobutyrate
该化合物是治疗丙型肝炎病毒(HCV)感染而研制的核素类比抑制剂,作为PSI-6130的一种药物,它以HCV RNA依赖的RNA聚合酶(NS5B)为对象,显示出强大的抗病毒活动,从而抑制了病毒复制;Mericitabine由于其行动机制而表现出很大的抗药性障碍,这涉及到在RNA合成过程中链条终止. 临床研究表明,它具有有利的药效动因和良好的安全性特征,其不利影响最小. 它与其他直接作用的抗病毒药物(DAAAs)的兼容性提高了其在综合疗法中的效用,为HCV基因1型和4型感染提供了很有希望的选择.
- 英文名称(2R,3R,4R,5R)-5-(4-Amino-2-Oxopyrimidin-1(2H)-yl)-4-Fluoro-2-((Isobutyryloxy)Methyl)-4-Methyltetrahydrofuran-3-Yl Isobutyrate
- 中文名称R7128;(2'R)-2'-去氧-2'-氟-2'-甲基胞苷3',5'-双(2-甲基丙酸)酯
- IUPAC名称(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-2-((isobutyryloxy)methyl)-4-methyltetrahydrofuran-3-yl isobutyrate
- CAS编号940908-79-2
- MFCD编号:MFCD22572932
- FDA UNII编号:TA63JX8X52
- 分子式:C18H26FN3O6分子量:399.42
- 产品CID: 1987118
- 产品分类生物化工 → 生化试剂 → 激动剂抑制剂
- 相似结构搜索
- InChIKey: MLESJYFEMSJZLZ-MAAOGQSESA-N
- MLESJYFEMSJZLZ-MAAOGQSESA-N
- 计算化学: 氢键受体数7.0氢键供体数1.0可旋转键数8.0
物理性质
MSDS等安全信息
上下游产品
4-氨基-1-((2R,3R,4R,5R)-3-氟-4-羟基-5-(羟基甲基)-3-甲基四氢呋喃-2-基)嘧啶-2(1H)-酮 (2'R)-2'-Deoxy-2'-Fluoro-2'-Methylcytidine 817204-33-4胞苷 Cytidine 65-46-3
苯甲酰胞苷 N4-Benzoylcytidine 13089-48-0
合成工艺路线路线简述
- 817204-33-4 + 79-30-1 = 940908-79-2
反应条件:1.1 Reagents: Triethylamine Catalysts: 4-(Dimethylamino)Pyridine Solvents: Tetrahydrofuran; 0 °C1.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 6.4
标题:Preparation Of Acylated (2'R)-2'-Deoxy-2'-Fluoro-2'-Methylcytidines As Antiviral Agents
参考文献:World Intellectual Property Organization]
= 940908-79-2 [标题:Reaction Conditions
标题:Preparation Of Substituted Nucleosides,Nucleotides And Analogs Thereof As Antiviral Agents
参考文献:World Intellectual Property Organization]
817204-33-4 + 79-30-1 = 940908-79-2
反应条件:1.1 Reagents: Triethylamine Catalysts: 4-(Dimethylamino)Pyridine Solvents: Tetrahydrofuran,Water; 40 °C; 40 °C -> 0 °C1.2 4 - 5 H,0 °C; 1 H,0 °C1.3 Reagents: Sulfuric Acid Solvents: Water; Ph 6 - 7,0 °C1.4 Solvents: Ethyl Acetate; 20 Min,0 °C1.5 Reagents: Sodium Hydroxide Solvents: Water; Ph 10.5 - 11,0 °C1.6 Solvents: Ethyl Acetate; 0 °C -> Rt; 2 H,Rt
标题:Process For The Preparation Of 2-Deoxy-2-Fluoro-2-Methyl-D-Ribofuranosyl Nucleosides As Potential Anti-Hcv And Ns5B Polymerase Inhibitors
参考文献:World Intellectual Property Organization]
817204-33-4 + 79-30-1 = 940908-79-2
反应条件:1.1 Reagents: Triethylamine Catalysts: 4-(Dimethylamino)Pyridine Solvents: Tetrahydrofuran,Water; 0 °C; 1.5 H,0 °C1.2 Reagents: Isobutyl Chloride1.3 Reagents: Hydrochloric Acid Solvents: Water; Ph 6.4
标题:Preparation Of Pyridazinylmethylimidazopyridine Derivatives And Analogs For Use In The Treatment Of Hepatitis C Virus Using Combination Chemotherapy
参考文献:World Intellectual Property Organization]
= 940908-79-2 [标题:Reaction Conditions
标题:Prepn Of Substituted Nucleosides,Nucleotides And Analogs Thereof As Antiviral Agents
参考文献:World Intellectual Property Organization]
= 940908-79-2 [标题:Reaction Conditions
标题:Preparation Of Substituted Nucleotide Phosphorothioate Analogs For Treating Viral Infections,Cancer,And/or Parasitic Diseases
参考文献:United States]
= 940908-79-2 [标题:Reaction Conditions
标题:Preparation Of Purine Nucleoside Phosphoramidate As Antiviral Agent
参考文献:World Intellectual Property Organization
📜胞苷置于吡啶,4-二甲氨基吡啶,三乙胺体系中,用 四氢呋喃,水,N,N-二甲基甲酰胺 作为反应溶剂,化学反应 20.0H,反应生成 R7128;(2'R)-2'-去氧-2'-氟-2'-甲基胞苷3',5'-双(2-甲基丙酸)酯
参考文献:Methods For Treating Hcv
标题:Methods For Treating Hcv
摘要:这项发明涉及治疗丙型肝炎病毒感染的治疗分子组合.本发明涉及方法,用途,给药方案和组合物.
海关参考信息
- 2905122000-异丙醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇
2905399001-1,3-丙二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-9573939-B2
优先权日:2011-09-08
标题:Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
发明人：MCCOMAS CASEY C; LIVERTON NIGEL J; HABERMANN JOERG; KOCH UWE; NARJES FRANK; LI PENG; PENG XUANJIA; SOLL RICHARD; WU HAO; PALANI ANANDAN; DAI XING; LIU HONG; HE SHUWEN; DANG QUN
权利人:MCCOMAS CASEY C; LIVERTON NIGEL J; HABERMANN JOERG; KOCH UWE; NARJES FRANK; LI PENG; PENG XUANJIA; SOLL RICHARD; WU HAO; PALANI ANANDAN; DAI XING; LIU HONG; HE SHUWEN; DANG QUN; MERCK SHARP & DOHME; MSD ITALIA SRL
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
专利号:US-2016130259-A1
优先权日:2013-06-24
标题 :Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
发明人：LIU HONG; DAI XING; PALANI ANANDAN; HE SHUWEN; NARGUND RAVI; XIAO DONG; DANG QUN; PENG XUANJIA; LI PENG
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
专利号:US-9364482-B2
优先权日:2013-06-24
标 题 :Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
发明人：DAI XING; LIU HONG; PALANI ANANDAN; HE SHUWEN; NARGUND RAVI; XIAO DONG; ZORN NICOLAS; DANG QUN; MCCOMAS CASEY C; PENG XUANJIA; LI PENG; SOLL RICHARD
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. (I)
专利号:US-9265773-B2
优先权日:2011-09-08
标题 :Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
发明人：MCCOMAS CASEY C; LIVERTON NIGEL J; HABERMANN JOERG; KOCH UWE; NARJES FRANK; LI PENG; PENG XUANJIA; SOLL RICHARD; WU HAO; PALANI ANANDAN; HE SHUWEN; DAI XING; LIU HONG; LAI ZHONG; LONDON CLARE; XIAO DONG; ZORN NICOLAS; NARGUND RAVI
权利人:MCCOMAS CASEY C; LIVERTON NIGEL J; HABERMANN JOERG; KOCH UWE; NARJES FRANK; LI PENG; PENG XUANJIA; SOLL RICHARD; WU HAO; PALANI ANANDAN; HE SHUWEN; DAI XING; LIU HONG; LAI ZHONG; LONDON CLARE; XIAO DONG; ZORN NICOLAS; NARGUND RAVI; MERCK SHARP & DOHME; MSD ITALIA SRL
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
专利号:US-9549917-B2
优先权日:2011-09-08
标 题 :Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
发明人：MCCOMAS CASEY C; LIVERTON NIGEL J; HABERMANN JOERG; KOCH UWE; NARJES FRANK; LI PENG; PENG XUANJIA; SOLL RICHARD; WU HAO; PALANI ANANDAN; DAI XING; LIU HONG; HE SHUWEN; LAI ZHONG; DANG QUN; ZORN NICOLAS
权利人:MCCOMAS CASEY C; LIVERTON NIGEL J; HABERMANN JOERG; KOCH UWE; NARJES FRANK; LI PENG; PENG XUANJIA; SOLL RICHARD; WU HAO; PALANI ANANDAN; DAI XING; LIU HONG; HE SHUWEN; LAI ZHONG; DANG QUN; ZORN NICOLAS; MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
专利号:US-9549921-B2
优先权日:2013-06-24
标 题:Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C
发明人：HE SHUWEN; LAI ZHONG; DAI XING; XIAO DONG; LONDON CLARE; ZORN NICOLAS; NARGUND RAVI; PALANI ANANDAN; MCCOMAS CASEY C; LI PENG; PENG XUANJIA; SOLL RICHARD
权利人:HE SHUWEN; LAI ZHONG; DAI XING; XIAO DONG; LONDON CLARE; ZORN NICOLAS; NARGUND RAVI; PALANI ANANDAN; MCCOMAS CASEY C; LI PENG; PENG XUANJIA; SOLL RICHARD; MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.(I)
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Wedemeyer H, Forns X, Hézode C, Lee SS, Scalori A, Voulgari A, Le Pogam S, Nájera I, Thommes JA. Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. PLoS One. 2016 Jan 11;11(1):e0145409. doi: 10.1371/journal.pone.0145409. eCollection 2016.
2: Feng JY, Xu Y, Barauskas O, Perry JK, Ahmadyar S, Stepan G, Yu H, Babusis D, Park Y, McCutcheon K, Perron M, Schultz BE, Sakowicz R, Ray AS. Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus. Antimicrob Agents Chemother. 2015 Nov 23;60(2):806-17. doi: 10.1128/AAC.01922-15. Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. Liver Int. 2015 Oct 31. doi: 10.1111/liv.12997. [Epub ahead of print] doi: 10.3851/IMP2879. Epub 2014 Oct 16.
6: Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, Jablkowski M, Berak H, Vierling JM, Yoshida EM, Perez-Gomez HR, Scalori A, Hooper GJ, Tavel JA, Navarro MT, Shahdad S, Kulkarni R, Le Pogam S, Nájera I, Eng S, Lim CY, Shulman NS, Yetzer ES. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015 Feb;62(2):294-302. doi: 10.1016/j.jhep.2014.09.013. Epub 2014 Sep 18. doi: 10.1371/journal.pone.0105569. eCollection 2014.
合成参考文献
参考文献:10.1007/s11684-014-0334-2
摘要:Pockros PJ. Advances in newly developing therapy for chronic hepatitis C virus infection. Front Med. 2014 Jun;8(2):166–74. doi: 10.1007/s11684-014-0334-2.
📝 需求与反馈
尽可能描述清楚需求与问题信息
